达拉图穆马
硼替佐米
地塞米松
医学
多发性骨髓瘤
肿瘤科
药品
耐火材料（行星科学）
内科学
药理学
生物
天体生物学
出处
期刊：Cancer Discovery
[American Association for Cancer Research]
日期：2016-09-15
卷期号：6 (11): OF4-OF4
被引量：2
标识
DOI：10.1158/2159-8290.cd-nb2016-115
摘要
A phase III trial suggests that the combination of daratumumab, bortezomib, and dexamethasone is more powerful in patients with relapsed or relapsed and refractory melanoma than bortezomib plus dexamethasone. Patients who received all three drugs had a higher overall response rate and improved 12-month progression-free survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
pcr163
科研狗
pluto
wanci
蓝莓橘子酱
Stella
Mic
yuriyc
Auston_zhong
GingerF
ffrrss
子车茗
null
老李
ilihe
sxb10101
寻道图强
ZOE
寒江雪
皖公网安备34019202002308
